Mobile Health Innovative Solutions v. Zepp Health: Voluntary Dismissal in AI Wearable Patent Case

Introduction

In a case that drew attention from the wearable health technology sector, Mobile Health Innovative Solutions, LLC voluntarily dismissed its patent infringement lawsuit against Zepp Health Corporation with prejudice — ending the dispute before Zepp Health ever filed an answer. Filed on August 8, 2024, in the Eastern District of Texas and closed on April 28, 2025, Case No. 2:24-cv-00651 centered on U.S. Patent No. US11468984B2, which covers AI-powered health monitoring technology embedded in consumer smartwatches.

The case targeted Zepp Health’s Amazfit GTR 4 smartwatch and its Zepp Aura platform — products that leverage artificial intelligence to assess user readiness, relaxation levels, and sleep quality. Though the litigation concluded without a merits ruling, the circumstances surrounding its rapid closure raise important questions about pre-litigation strategy, patent assertion entity behavior, and the growing complexity of **AI wearable patent infringement** claims in the smartwatch market.

For patent attorneys, IP professionals, and R&D teams operating in the digital health and wearable technology space, this case offers meaningful signals about assertion strategy and litigation risk management.

Case Overview

The Parties

The Patent at Issue

At the center of the dispute was **U.S. Patent No. US11468984B2** (Application No. US16/850984). The patent covers technology related to AI-powered user load assessment — specifically, systems and methods for measuring a user’s readiness and relaxation level (described as “current load level”) and interpreting physiological data to support health insights, including sleep pattern analysis.

The Accused Products

The complaint identified **Amazfit GTR 4** smartwatches and the **Zepp Aura** platform as the accused products. Zepp Aura, an AI-powered sleep and wellness coaching service integrated with Amazfit devices, specifically offers readiness scoring, relaxation measurement, and sleep analysis — functionalities allegedly mapping to the claimed invention in US11468984B2.

Legal Representation

Plaintiff Mobile Health Innovative Solutions was represented by attorney **Randall T. Garteiser** of **Garteiser Honea PLLC**, a Texas-based intellectual property litigation firm with an established presence in the Eastern District of Texas. No defendant counsel was entered into the record prior to dismissal.

Litigation Timeline & Procedural History

The case was filed in the **U.S. District Court for the Eastern District of Texas**, presided over by **Chief Judge Rodney Gilstrap** — one of the most experienced and prolific patent trial judges in the United States. Judge Gilstrap’s court handles a disproportionate share of the nation’s patent litigation docket, making venue selection here a deliberate strategic choice by plaintiff’s counsel.

Critically, the case concluded at the **first instance (district court) level** via **Plaintiff’s Notice of Voluntary Dismissal with Prejudice** filed under **Federal Rule of Civil Procedure 41(a)(1)(A)(i)**. This procedural mechanism is available only before the defendant has served an answer or a motion for summary judgment — a significant procedural detail confirming that Zepp Health had not yet formally responded when the dismissal was filed.

The 263-day duration, while spanning nearly nine months on the docket, reflects a pre-answer resolution — meaning no substantive litigation milestones such as claim construction, discovery, or motion practice were completed on the merits.

The Verdict & Legal Analysis

Outcome

The court accepted and acknowledged the **voluntary dismissal with prejudice** on April 28, 2025. Per the order, **each party bears its own costs, expenses, and attorneys’ fees**, and all pending requests for relief were dismissed as moot. No damages were awarded. No injunctive relief was granted. There was no finding on the merits of infringement, validity, or claim construction.

A dismissal **with prejudice** is legally significant: it operates as a final adjudication on the merits under res judicata principles, permanently barring Mobile Health Innovative Solutions from re-filing the same claims against Zepp Health based on the same patent and accused products.

Verdict Cause Analysis

The complaint’s underlying theory — that Zepp Health’s Amazfit GTR 4 and Zepp Aura platform infringed US11468984B2 through AI-driven load level assessment and sleep monitoring — was never tested before the court. The absence of a defendant answer or summary judgment motion prior to dismissal indicates the litigation was resolved, or strategically abandoned, entirely outside formal court proceedings.

While the specific reasons for voluntary dismissal are not disclosed in the record, common drivers in comparable PAE (patent assertion entity) litigation include:

• Out-of-court licensing resolution — a confidential settlement or licensing agreement reached between the parties
• Claim viability reassessment — plaintiff counsel’s determination that infringement or validity arguments would not withstand scrutiny
• Pre-suit negotiation outcomes — resolution of the commercial dispute prior to defendant engagement in formal litigation
• Strategic withdrawal — preserving resources in anticipation of reasserted claims against different defendants

The “with prejudice” designation, however, forecloses refiling against this defendant — distinguishing this outcome from a tactical dismissal without prejudice designed to reset litigation timelines.

Legal Significance

This case does not establish binding precedent, as it resolved without a merits ruling. However, it contributes to observable patterns in **AI health wearable patent infringement litigation**, particularly the use of the Eastern District of Texas as a preferred venue for NPE (non-practicing entity) assertions against consumer technology companies.

The patent at issue — covering AI-based physiological load assessment — sits at the convergence of several legally active claim categories: software-implemented inventions, AI/machine learning methods, and health data analytics. Claims in this space remain subject to continued scrutiny under **35 U.S.C. § 101** (patent eligibility), making pre-answer dismissals plausible where claim viability is uncertain.

Industry & Competitive Implications

The Mobile Health Innovative Solutions v. Zepp Health case reflects an accelerating trend: patent assertion activity targeting AI-enabled consumer health wearables. As smartwatch platforms integrate increasingly sophisticated physiological monitoring capabilities — sleep staging, stress scoring, readiness indices — they present expanding surfaces for patent assertions rooted in health data AI methodology.

Zepp Health’s Amazfit and Zepp Aura product lines compete in a crowded market alongside Apple Watch, Fitbit/Google, Garmin, and Samsung Galaxy Watch — all of which embed comparable AI health intelligence features. The assertion of US11468984B2 signals that IP portfolios covering “current load level” measurement and sleep readiness AI may be leveraged broadly across this competitive landscape.

For companies in the digital health and wearables sector, this case underscores the importance of proactive IP landscaping. R&D investment in AI health features should be accompanied by systematic FTO review, particularly for patents covering adaptive load assessment, physiological readiness scoring, and AI-driven sleep analysis — claim categories now demonstrably in active assertion.

The Eastern District of Texas remains a strategically favored venue. IP teams should monitor dockets in this jurisdiction for emerging assertion patterns targeting wearable and mobile health technology.

FAQ

What patents were involved in Mobile Health Innovative Solutions v. Zepp Health?

The case involved U.S. Patent No. US11468984B2 (Application No. US16/850984), covering AI-powered systems for measuring user readiness and load levels with applications in sleep and health monitoring.

What was the basis for dismissal in Case No. 2:24-cv-00651?

Plaintiff filed a Notice of Voluntary Dismissal with Prejudice under FRCP 41(a)(1)(A)(i) before Zepp Health filed an answer or summary judgment motion. The court accepted the dismissal on April 28, 2025.

How might this case affect AI wearable patent litigation?

While non-precedential, the case signals active patent assertion targeting AI health scoring features in consumer wearables. Companies with similar product capabilities — sleep AI, readiness metrics — should conduct proactive FTO analyses.

*For access to the full case docket, visit PACER and search Case No. 2:24-cv-00651 (E.D. Tex.). Patent details for US11468984B2 are available on the USPTO Patent Full-Text Database.*